Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 18/20 | 0.77 |
| ▸ | RARB | P10826 | 16/20 | 0.77 |
| ▸ | RARA | P10276 | 15/20 | 0.77 |
| ▸ | RXRA | P19793 | 14/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | THPO | P40225 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temarotene SCHEMBL7544424 | 1.00 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL29363514 | 1.00 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL5999341 | 1.00 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL10723294 | 0.96 | RARG (0.71) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL980221 | 0.93 | RARG (0.72) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL9859887 | 0.92 | RARG (0.74) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL8949941 | 0.92 | RARG (0.74) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL8776376 | 0.92 | RARG (0.74) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL8776527 | 0.91 | RARG (0.64) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL8776530 | 0.91 | RARG (0.64) | RARGRARBRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20230346734-A1 | COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2023-11-02 | — | — | US | claimed |
| EP-4136111-A1 | COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA | Julius-Maximilians-Universität Würzburg (DE) | 2023-02-22 | — | — | EP | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| WO-2021209498-A1 | COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2021-10-21 | — | — | WO | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020141648-A1 | NOVEL GLIA-LIKE CELLS DIFFERENTIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | 성균관대학교산학협력단 | 2020-07-09 | — | — | WO | claimed |
| EP-2800776-B1 | SILICONE ADHESIVE COMPOSITIONS | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-04-29 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| US-5019569-A | Topical Administritation of Retinoids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-05-28 | — | — | US | claimed |
| EP-0415766-A2 | Use of retinoids for reversing glucocorticoid-induced skin atrophy | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| US-4889847-A | USED IN CONJUCTION WITH A RETINOID COMPOUND | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-12-26 | — | — | US | claimed |
| US-4877805-A | REVERSING COLLAGEN FIBER LOSS BY APPLYING TO FACE | KLIGMAN ALBERT M (US) | 1989-10-31 | — | — | US | claimed |
| US-4863969-A | Treatment of premalignant lesions and certain malignant tumors | HOFFMANN-LA ROCHE INC. (US) | 1989-09-05 | — | — | US | claimed |
| EP-0266992-A2 | Prevention of glucocorticoid-induced skin atrophy | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-05-11 | — | — | EP | claimed |
| US-4689350-A | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYL-6-(ALPHA-METHYLSTYRYL) NAPHTHALENE | HOFFMAN-LA ROCHE INC. (US) | 1987-08-25 | — | — | US | claimed |
| EP-0212137-A2 | Use of a retinoid for the manufacture of a cytostatic agent. | F. HOFFMANN-LA ROCHE AG (CH) | 1987-03-04 | — | — | EP | claimed |
| EP-0207421-A2 | Use of a retinoid for the manufacture of an anti-keratinizing medicament | F. HOFFMANN-LA ROCHE AG (CH) | 1987-01-07 | — | — | EP | claimed |
| US-4588750-A | A TETRAHYDRO-TETRAMETHYL-NAPHTHALENE, ANTDANDRUFF, ANTIACNE | HOFFMANN-LA ROCHE INC. (US) | 1986-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | RARG 2964/4885RARB 3393/4885RARA 2554/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | RARG 134/4885RARB 70/4885RARA 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.